Literature DB >> 387328

Effects of carbamazepine on valproic acid kinetics in normal subjects.

T A Bowdle, R H Levy, R E Cutler.   

Abstract

Carbamazepine and valproic acid are used together in the treatment of epilepsy. It is therefore, relevant to investigate the possibility of a carbamazepine effect on valproic acid disposition, particularly since carbamazepine is known to induce enzymes. We gave valproic acid orally to 6 normal subjects, 250 mg twice daily for 4 wk. Carbamazepine, 200 mg once daily, was begun after 4 days on valproic acid. Serum drug concentrations were measured during 4 dosing intervals, once before and 3 times after beginning carbamazepine. Minimum steady-state concentrations of valproic acid declined after carbamazepine from 34.4 +/- 5.1 to 27.1 +/- 4.4 mug/ml (p less than 0.0005). Clearance rose from 6.46 +/- 0.80 to 8.48 +/- 2.28 ml/hr/kg (p less than 0.01). The increase in clearanace and decrease in minimum steady-state levels was apparent only after 2 wk on carbamazepine. The elimination rate constant (KE) during the dosing interval did not rise during carbamazepine administration (0.0623 +/- 0.0168 hr--1 before and 0.0573 +/- 0.0168 hr--1 after, p greater than 0.25), raising the possibility of an increase in distribution volume.

Entities:  

Mesh:

Substances:

Year:  1979        PMID: 387328     DOI: 10.1002/cpt1979265629

Source DB:  PubMed          Journal:  Clin Pharmacol Ther        ISSN: 0009-9236            Impact factor:   6.875


  13 in total

1.  The effects of phenytoin and carbamazepine on serum concentrations of mono-unsaturated metabolites of valproic acid.

Authors:  T Kondo; K Otani; T Hirano; S Kaneko; Y Fukushima
Journal:  Br J Clin Pharmacol       Date:  1990-01       Impact factor: 4.335

Review 2.  Clinically significant pharmacokinetic drug interactions with carbamazepine. An update.

Authors:  E Spina; F Pisani; E Perucca
Journal:  Clin Pharmacokinet       Date:  1996-09       Impact factor: 6.447

Review 3.  Pharmacokinetic interactions between antiepileptic drugs. Clinical considerations.

Authors:  R Riva; F Albani; M Contin; A Baruzzi
Journal:  Clin Pharmacokinet       Date:  1996-12       Impact factor: 6.447

4.  Possible interaction between phenobarbital, carbamazepine and itraconazole.

Authors:  M Bonay; A P Jonville-Bera; P Diot; E Lemarie; M Lavandier; E Autret
Journal:  Drug Saf       Date:  1993-10       Impact factor: 5.606

Review 5.  Application of stable labelled drugs in clinical pharmacokinetic investigations.

Authors:  M Eichelbaum; G E von Unruh; A Somogyi
Journal:  Clin Pharmacokinet       Date:  1982 Nov-Dec       Impact factor: 6.447

Review 6.  Pharmacokinetic interactions with antiepileptic drugs.

Authors:  E Perucca
Journal:  Clin Pharmacokinet       Date:  1982 Jan-Feb       Impact factor: 6.447

7.  Effect of sodium valproate on carbamazepine disposition and psychomotor profile in man.

Authors:  G J Macphee; J R Mitchell; L Wiseman; A R McLellan; B K Park; G T McInnes; M J Brodie
Journal:  Br J Clin Pharmacol       Date:  1988-01       Impact factor: 4.335

8.  The influence of free fatty acids on valproic acid plasma protein binding during fasting in normal humans.

Authors:  T A Bowdle; I H Patel; R H Levy; A J Wilensky
Journal:  Eur J Clin Pharmacol       Date:  1982-10       Impact factor: 2.953

Review 9.  Drug interactions with valproic acid.

Authors:  R H Levy; K M Koch
Journal:  Drugs       Date:  1982-12       Impact factor: 9.546

10.  The effect of carbamazepine on valproic acid disposition in adult volunteers.

Authors:  S K Panesar; J M Orr; K Farrell; R W Burton; K Kassahun; F S Abbott
Journal:  Br J Clin Pharmacol       Date:  1989-03       Impact factor: 4.335

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.